Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction

14. November 2026 aktualisiert von: Yu Jie, Chinese PLA General Hospital

Multimodal Ultrasound-Based Intelligent Classification and Treatment Response Prediction in the Dynamic Evolution of Lymphoma

This prospective, multicenter, observational cohort study aims to evaluate whether multimodal ultrasound can support the noninvasive classification of lymphoma and the early prediction of treatment response.

Adults with newly diagnosed and previously untreated lymphoma will undergo standardized multimodal ultrasound examinations before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. Ultrasound examinations will include B-mode ultrasound, color Doppler flow imaging, contrast-enhanced ultrasound, super-resolution contrast-enhanced ultrasound, and ultrasound viscoelasticity imaging. Clinical, laboratory, pathological, molecular, treatment, and follow-up information will also be collected.

The study will investigate differences in ultrasound characteristics among lymphoma subtypes, evaluate changes in ultrasound features during treatment, and develop and validate prediction models integrating imaging and clinical information. The main hypothesis is that multimodal ultrasound features and their early treatment-related changes reflect the biological heterogeneity of lymphoma and can improve noninvasive lymphoma classification and early prediction of treatment response.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a prospective, multicenter, observational cohort study of adults with newly diagnosed, previously untreated lymphoma. The study plans to prospectively enroll approximately 2,000 participants across participating centers.

Standardized multimodal ultrasound data will be collected at predefined time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during subsequent follow-up. Imaging modalities include B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Clinical and laboratory information, treatment information, pathological diagnosis, immunohistochemical findings, molecular and genetic test results, and follow-up information will also be collected.

The study will first characterize multimodal ultrasound phenotypes across lymphoma categories, including Hodgkin lymphoma and non-Hodgkin lymphoma, indolent and aggressive non-Hodgkin lymphoma, and common pathological subtypes. Longitudinal changes in ultrasound features during treatment will then be evaluated to identify imaging characteristics associated with treatment response.

Using the collected multimodal imaging and clinical data, statistical and machine-learning approaches will be used to develop and validate models for lymphoma classification and early treatment-response prediction. Model development will incorporate imaging features from multiple ultrasound modalities together with relevant clinical information. Model performance will be evaluated using measures of discrimination, calibration, and clinical utility, as appropriate.

The overall objective is to determine whether multimodal ultrasound can provide a noninvasive and repeatable approach for characterizing lymphoma heterogeneity and for identifying treatment response at an earlier stage of therapy.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

2000

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100853
        • Rekrutierung
        • Chinese PLA General Hospital
        • Kontakt:
        • Hauptermittler:
          • Jie Yu, PhD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adults with histopathologically confirmed, newly diagnosed, previously untreated lymphoma who present to participating study centers and have at least one lesion suitable for standardized multimodal ultrasound evaluation will be prospectively enrolled.

Beschreibung

Inclusion Criteria:

  1. Age 18 years or older.
  2. Histopathologically confirmed lymphoma.
  3. Newly diagnosed and previously untreated, with no prior radiotherapy, chemotherapy, targeted therapy, immunotherapy, or other systemic antitumor treatment before enrollment.
  4. At least one superficial or otherwise accessible lesion that can be clearly evaluated by ultrasound, such as a cervical, axillary, or inguinal lymph node, with an adequate acoustic window allowing stable acquisition of all five ultrasound modalities.
  5. Expected survival of more than 3 months.
  6. No contraindication to the use of ultrasound contrast agents.
  7. Willingness to undergo multimodal ultrasound examinations before, during, and after treatment and provision of written informed consent.

Exclusion Criteria:

  1. Target lesion located too deeply or obscured by gas or bone, preventing acquisition of a stable ultrasound imaging plane.
  2. Known history of hypersensitivity to any component of the ultrasound contrast agent (sulfur hexafluoride microbubbles).
  3. Known right-to-left cardiac shunt, severe pulmonary hypertension with pulmonary artery pressure greater than 90 mmHg, or uncontrolled hypertension.
  4. Acute respiratory distress syndrome or severe respiratory insufficiency.
  5. Unstable angina or acute myocardial infarction within the previous 1 week.
  6. Pregnancy or breastfeeding.
  7. Inability, in the investigator's judgment, to cooperate with the complete examination procedure or complete the required follow-up.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Newly Diagnosed Untreated Lymphoma Cohort

Adults with pathologically confirmed, newly diagnosed, previously untreated lymphoma who undergo longitudinal multimodal ultrasound examinations and clinical follow-up according to the study protocol.

Participants undergo standardized multimodal ultrasound examinations including B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Examinations are performed at predefined study time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. The imaging findings are collected for lymphoma classification and treatment-response prediction.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Area Under the Receiver Operating Characteristic Curve for Differentiating Hodgkin Lymphoma From Non-Hodgkin Lymphoma
Zeitfenster: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing Hodgkin lymphoma from non-Hodgkin lymphoma, using histopathological diagnosis as the reference standard.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Area Under the Receiver Operating Characteristic Curve for Differentiating Indolent From Aggressive Non-Hodgkin Lymphoma
Zeitfenster: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing indolent from aggressive non-Hodgkin lymphoma, using histopathological classification as the reference standard.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Area Under the Receiver Operating Characteristic Curve for Predicting Complete Response After the Fourth Treatment Cycle Using First-Cycle Multimodal Ultrasound
Zeitfenster: After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).

The area under the receiver operating characteristic curve (AUC) will be used to evaluate the ability of the multimodal ultrasound model to predict complete response (CR) after completion of Cycle 4, using ultrasound features obtained after completion of Cycle 1. Complete response will be assessed by PET/CT or CT according to the study protocol. Each treatment cycle is scheduled to last 21 or 28 days, depending on the prescribed first-line regimen. Assessments are linked to completion of the relevant treatment cycle; the estimated calendar times assume no treatment delays.

After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Sensitivity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
Zeitfenster: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The percentage of participants with histopathologically confirmed Hodgkin lymphoma who are correctly classified as having Hodgkin lymphoma by the multimodal ultrasound model.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Specificity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
Zeitfenster: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The percentage of participants with histopathologically confirmed non-Hodgkin lymphoma who are correctly classified as not having Hodgkin lymphoma by the multimodal ultrasound model.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Sensitivity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
Zeitfenster: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The percentage of participants with histopathologically confirmed aggressive non-Hodgkin lymphoma who are correctly classified as having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Specificity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
Zeitfenster: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The percentage of participants with histopathologically confirmed indolent non-Hodgkin lymphoma who are correctly classified as not having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Classification Accuracy of the Multimodal Ultrasound Model for Common Lymphoma Subtypes
Zeitfenster: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The proportion of participants whose lymphoma subtype is correctly classified by the multimodal ultrasound model, using histopathological diagnosis as the reference standard.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Correlation Between Multimodal Ultrasound Parameters and Tumor Cell Density
Zeitfenster: At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.

The association between quantitative multimodal ultrasound parameters and tumor cell density determined by pathological assessment will be evaluated using correlation analysis.

At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
Correlation Between Multimodal Ultrasound Parameters and Pathological Microvessel Density
Zeitfenster: At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.

The association between quantitative multimodal ultrasound parameters and microvessel density determined by pathological assessment will be evaluated using correlation analysis.

At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Progression-Free Survival
Zeitfenster: From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.

The prognostic performance of the multimodal ultrasound model for predicting 2-year progression-free survival (PFS) will be evaluated using the concordance index (C-index). PFS is defined as the time from the date of initial histopathological diagnosis of lymphoma to the first documented disease progression, relapse, or death from any cause, whichever occurs first.

From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Overall Survival
Zeitfenster: From enrollment to death from any cause, assessed through 24 months after enrollment.

The prognostic performance of the multimodal ultrasound model for predicting 2-year overall survival (OS) will be evaluated using the concordance index (C-index). OS is defined as the time from the date of initial histopathological diagnosis of lymphoma to death from any cause.

From enrollment to death from any cause, assessed through 24 months after enrollment.
Comparison of Area Under the Receiver Operating Characteristic Curves Between the Multimodal Ultrasound Model and Radiologists
Zeitfenster: At the pretreatment baseline assessment, before initiation of antitumor treatment.

The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model will be compared with that of radiologists for lymphoma classification, using histopathological diagnosis as the reference standard.

At the pretreatment baseline assessment, before initiation of antitumor treatment.
Incidence of Study Ultrasound-Related Adverse Events
Zeitfenster: From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.

The number and proportion of participants experiencing adverse events related to study ultrasound examinations, particularly contrast-enhanced ultrasound, will be recorded. Contrast-agent-related adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Serious adverse reactions will also be documented.

From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Jie Yu, PhD, Chinese PLA General Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Januar 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2029

Studienabschluss (Geschätzt)

1. Dezember 2031

Studienanmeldedaten

Zuerst eingereicht

4. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. November 2026

Zuerst gepostet (Tatsächlich)

17. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 2026-532
  • U25C2048 (Andere Zuschuss-/Finanzierungsnummer: National Natural Science Foundation of China)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .